Literature DB >> 21388312

Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

Vince D Cataldo1, Don L Gibbons, Román Pérez-Soler, Alfonso Quintás-Cardama.   

Abstract

A 64-year-old woman receives the diagnosis of metastatic non-small-cell lung cancer (NSCLC), which has progressed during treatment with carboplatin, paclitaxel, and bevacizumab. Erlotinib therapy is recommended.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21388312     DOI： 10.1056/NEJMct0807960

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


  133 in total

1.  ψ-Bufarenogin, a lead compound of anti-cancer drug.

Authors:  Jin Ding; Hongyang Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma.

Authors:  Sweta Rani; Kathy Gately; John Crown; Ken O'Byrne; Lorraine O'Driscoll
Journal:  Cancer Biol Ther       Date:  2013-09-04       Impact factor: 4.742

3.  Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.

Authors:  Osamu Takahashi; Ritsuko Komaki; Paul D Smith; Juliane M Jürgensmeier; Anderson Ryan; B Nebiyou Bekele; Ignacio I Wistuba; Jörg J Jacoby; Maria V Korshunova; Anna Biernacka; Baruch Erez; Keiko Hosho; Roy S Herbst; Michael S O'Reilly
Journal:  Clin Cancer Res       Date:  2012-01-24       Impact factor: 12.531

Review 4.  The quest to overcome resistance to EGFR-targeted therapies in cancer.

Authors:  Curtis R Chong; Pasi A Jänne
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

Review 5.  Afatinib treatment in advanced non-small cell lung cancer.

Authors:  Jane L Hurwitz; Paula Scullin; Lynn Campbell
Journal:  Lung Cancer (Auckl)       Date:  2011-10-06

6.  Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.

Authors:  Fanghui Lu; Ying Chen; Chuntao Zhao; Haibo Wang; Danyang He; Lingli Xu; Jincheng Wang; Xuelian He; Yaqi Deng; Ellen E Lu; Xue Liu; Ravinder Verma; Hong Bu; Rachid Drissi; Maryam Fouladi; Anat O Stemmer-Rachamimov; Dennis Burns; Mei Xin; Joshua B Rubin; El Mustapha Bahassi; Peter Canoll; Eric C Holland; Q Richard Lu
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

7.  Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysis.

Authors:  Miaomiao Sheng; Yueguang Zhao; Fang Wang; Shanshan Li; Xiaojie Wang; Tao Shou; Ying Luo; Wenru Tang
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

Review 8.  Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy.

Authors:  Jason H Tang; David Chia
Journal:  Crit Rev Oncog       Date:  2015

Review 9.  Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Authors:  Emily H Castellanos; Leora Horn
Journal:  Oncologist       Date:  2016-04-06

10.  Development and validation of a spectrofluorimetric method for the determination of erlotinib in spiked human plasma.

Authors:  Bivash Mandal; Pavan Balabathula; Nivesh Mittal; George C Wood; Himanshu Bhattacharjee
Journal:  J Fluoresc       Date:  2012-08-09       Impact factor: 2.217
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.